Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs By Ogkologos - July 28, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPETE study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June... June 17, 2022 Making Cancer Clinical Trials Available to More Patients March 7, 2019 Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... January 31, 2022 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Load more HOT NEWS Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... Combining existing drugs improves prostate cancer survival Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic...
